Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells

por Stefka, A T, Park, J-H, Matsuo, Y, Chung, S, Nakamura, Y, Jakubowiak, A J, Rosebeck, S
Publicado 2016

Potent anti‐myeloma activity of the TOPK inhibitor OTS514 in pre‐clinical models

por Stefka, Andrew T., Johnson, David, Rosebeck, Shaun, Park, Jae‐Hyun, Nakamura, Yusuke, Jakubowiak, Andrzej J.
Publicado 2019

The API2-MALT1 Fusion Exploits TNFR Pathway-associated RIP1 Ubiquitination to Promote Oncogenic NF-κB Signaling

por Rosebeck, Shaun, Rehman, Aasia O., Apel, Ingrid J., Kohrt, Dawn, Appert, Alex, O’Donnell, Marie Anne, Ting, Adrian T., Du, Ming-Qing, Baens, Mathijs, Lucas, Peter C., McAllister-Lucas, Linda M.
Publicado 2013

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

por Jakubowiak, Andrzej J., Jasielec, Jagoda K., Rosenbaum, Cara A., Cole, Craig E., Chari, Ajai, Mikhael, Joseph, Nam, Jennifer, McIver, Amanda, Severson, Erica, Stephens, Leonor A., Tinari, Kathryn, Rosebeck, Shaun, Zimmerman, Todd M., Hycner, Tyler, Turowski, Agata, Karrison, Theodore, Zonder, Jeffrey A.
Publicado 2019